S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Flexion Therapeutics Stock Forecast, Price & News

-0.06 (-0.54 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $11.02
50-Day Range
MA: $12.09
52-Week Range
Now: $11.02
Volume875,000 shs
Average Volume578,316 shs
Market Capitalization$543.45 million
P/E RatioN/A
Dividend YieldN/A
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201, a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, an administered NaV1.7 inhibitor for the management of post-operative pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Flexion Therapeutics logo


Is FLXN A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
FLXN Dec 2020 12.500 put
November 23, 2020 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FLXN
Year FoundedN/A



Sales & Book Value

Annual Sales$72.96 million
Book Value($0.53) per share


Net Income$-149,770,000.00
Net Margins-153.90%


Market Cap$543.45 million
Next Earnings Date3/11/2021 (Estimated)


Overall MarketRank

1.43 out of 5 stars

Medical Sector

545th out of 1,962 stocks

Pharmaceutical Preparations Industry

261st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.06 (-0.54 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLXN News and Ratings via Email

Sign-up to receive the latest news and ratings for FLXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Flexion Therapeutics (NASDAQ:FLXN) Frequently Asked Questions

Is Flexion Therapeutics a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Flexion Therapeutics stock.
View analyst ratings for Flexion Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Flexion Therapeutics?

Wall Street analysts have given Flexion Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Flexion Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Flexion Therapeutics' next earnings date?

Flexion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Flexion Therapeutics

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings data on Wednesday, November, 4th. The specialty pharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The specialty pharmaceutical company earned $23.66 million during the quarter, compared to the consensus estimate of $23.59 million.
View Flexion Therapeutics' earnings history

How has Flexion Therapeutics' stock been impacted by Coronavirus?

Flexion Therapeutics' stock was trading at $12.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FLXN shares have decreased by 10.5% and is now trading at $11.02.
View which stocks have been most impacted by COVID-19

What guidance has Flexion Therapeutics issued on next quarter's earnings?

Flexion Therapeutics updated its FY 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $85.5-85.5 million, compared to the consensus revenue estimate of $84.88 million.

What price target have analysts set for FLXN?

12 equities research analysts have issued 1-year price objectives for Flexion Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they anticipate Flexion Therapeutics' stock price to reach $20.25 in the next year. This suggests a possible upside of 83.8% from the stock's current price.
View analysts' price targets for Flexion Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the following people:
  • Dr. Michael D. Clayman, Co-Founder, Pres, CEO & Director (Age 69, Pay $1.06M)
  • Dr. Neil Bodick, Consultant (Age 74, Pay $657.6k)
  • Dr. Scott D. Kelley, Chief Medical Officer (Age 62, Pay $626.53k)
  • Mr. David A. Arkowitz M.B.A., Chief Financial Officer (Age 60)
  • Scott Young, VP of Corp. Communications & Investor Relations
  • Ms. Carolyn Beaty Scimemi, VP, Legal Affairs & Chief Compliance Officer
  • Mr. Mark S. Levine, Gen. Counsel & Corp. Sec. (Age 48)
  • Mr. John Magee, VP of Sales
  • Ms. Christina Willwerth, Chief Strategy Officer (Age 50)
  • Ms. Kerry A. Wentworth, Chief Regulatory Officer (Age 48)

What is Mike Clayman, MD's approval rating as Flexion Therapeutics' CEO?

46 employees have rated Flexion Therapeutics CEO Mike Clayman, MD on Glassdoor.com. Mike Clayman, MD has an approval rating of 85% among Flexion Therapeutics' employees.

Who are some of Flexion Therapeutics' key competitors?

What other stocks do shareholders of Flexion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Aduro Biotech (ADRO), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Verastem (VSTM).

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Who are Flexion Therapeutics' major shareholders?

Flexion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.80%), Artisan Partners Limited Partnership (6.24%), Orbimed Advisors LLC (4.68%), Schroder Investment Management Group (1.30%), Royce & Associates LP (1.27%) and Northern Trust Corp (1.09%). Company insiders that own Flexion Therapeutics stock include Adam Muzikant, C Ann Merrifield, David Arkowitz, Mark S Levine, Mark Stejbach, Melissa Layman, Michael D Clayman and Samuel D Colella.
View institutional ownership trends for Flexion Therapeutics

Which institutional investors are selling Flexion Therapeutics stock?

FLXN stock was sold by a variety of institutional investors in the last quarter, including Royce & Associates LP, Squarepoint Ops LLC, Peregrine Capital Management LLC, Northern Trust Corp, Monarch Partners Asset Management LLC, Brandywine Global Investment Management LLC, and Dupont Capital Management Corp. Company insiders that have sold Flexion Therapeutics company stock in the last year include Adam Muzikant, David Arkowitz, Mark S Levine, and Melissa Layman.
View insider buying and selling activity for Flexion Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Flexion Therapeutics stock?

FLXN stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Artisan Partners Limited Partnership, BlackRock Inc., Essex Investment Management Co. LLC, JPMorgan Chase & Co., Vontobel Holding Ltd., CM Management LLC, and New York State Common Retirement Fund. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Mark Stejbach, Michael D Clayman, and Samuel D Colella.
View insider buying and selling activity for Flexion Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Flexion Therapeutics?

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Flexion Therapeutics' stock price today?

One share of FLXN stock can currently be purchased for approximately $11.02.

How much money does Flexion Therapeutics make?

Flexion Therapeutics has a market capitalization of $543.45 million and generates $72.96 million in revenue each year. The specialty pharmaceutical company earns $-149,770,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.

How many employees does Flexion Therapeutics have?

Flexion Therapeutics employs 288 workers across the globe.

What is Flexion Therapeutics' official website?

The official website for Flexion Therapeutics is www.flexiontherapeutics.com.

Where are Flexion Therapeutics' headquarters?

Flexion Therapeutics is headquartered at 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803.

How can I contact Flexion Therapeutics?

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]

This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.